Connection

James Norris to Animals

Back to Details
This is a "connection" page, showing publications James Norris has written about Animals.
James Norris
Connection Strength
0.334
Animals
  1. The sphingolipid response to cancer therapy. Adv Cancer Res. 2013; 117:xiii-xvii.
    View in: PubMed
    Score: 0.031
  2. Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines. J Urol. 2012 Aug; 188(2):632-8.
    View in: PubMed
    Score: 0.030
  3. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
    View in: PubMed
    Score: 0.025
  4. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
    View in: PubMed
    Score: 0.022
  5. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63.
    View in: PubMed
    Score: 0.021
  6. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
    View in: PubMed
    Score: 0.020
  7. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
    View in: PubMed
    Score: 0.020
  8. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003 Apr; 47(4):1301-7.
    View in: PubMed
    Score: 0.016
  9. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219.
    View in: PubMed
    Score: 0.013
  10. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. Adv Cancer Res. 2018; 140:265-293.
    View in: PubMed
    Score: 0.011
  11. Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
    View in: PubMed
    Score: 0.011
  12. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017 02; 1863(2):386-394.
    View in: PubMed
    Score: 0.010
  13. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
    View in: PubMed
    Score: 0.010
  14. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One. 2013; 8(10):e76593.
    View in: PubMed
    Score: 0.008
  15. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
    View in: PubMed
    Score: 0.008
  16. Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36.
    View in: PubMed
    Score: 0.008
  17. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78.
    View in: PubMed
    Score: 0.008
  18. Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck. 2012 Nov; 34(11):1628-33.
    View in: PubMed
    Score: 0.007
  19. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer. 2010 May 15; 126(10):2319-29.
    View in: PubMed
    Score: 0.007
  20. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
    View in: PubMed
    Score: 0.006
  21. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
    View in: PubMed
    Score: 0.006
  22. Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res. 2008; 49(3):265-9.
    View in: PubMed
    Score: 0.006
  23. Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle. 2008 Jan 15; 7(2):205-15.
    View in: PubMed
    Score: 0.006
  24. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
    View in: PubMed
    Score: 0.005
  25. Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther. 2007 Jun; 15(6):1065-71.
    View in: PubMed
    Score: 0.005
  26. Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem. 2006 Aug 25; 281(34):24695-703.
    View in: PubMed
    Score: 0.005
  27. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
    View in: PubMed
    Score: 0.004
  28. CD95 rapidly clusters in cells of diverse origins. Cancer Biol Ther. 2003 Jul-Aug; 2(4):392-5.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.